Brokerages Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) PT at $4.53

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has received an average recommendation of “Hold” from the seven brokerages that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $4.5333.

A number of equities research analysts have recently weighed in on the company. Wedbush reiterated a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Tuesday, November 11th. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 price target on shares of Zentalis Pharmaceuticals in a research note on Tuesday, November 11th. Wall Street Zen raised shares of Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Morgan Stanley decreased their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating for the company in a report on Wednesday, November 12th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a research note on Wednesday, October 8th.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, major shareholder Matrix Capital Management Comp sold 7,500,000 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $1.33, for a total transaction of $9,975,000.00. Following the transaction, the insider owned 6,459,973 shares in the company, valued at approximately $8,591,764.09. This represents a 53.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Invesco Ltd. grew its stake in Zentalis Pharmaceuticals by 193.8% in the first quarter. Invesco Ltd. now owns 149,484 shares of the company’s stock worth $238,000 after purchasing an additional 98,612 shares during the period. American Century Companies Inc. lifted its position in Zentalis Pharmaceuticals by 46.2% during the first quarter. American Century Companies Inc. now owns 46,900 shares of the company’s stock valued at $75,000 after buying an additional 14,816 shares during the period. Ieq Capital LLC boosted its holdings in shares of Zentalis Pharmaceuticals by 521.4% during the 1st quarter. Ieq Capital LLC now owns 93,920 shares of the company’s stock valued at $149,000 after buying an additional 78,805 shares in the last quarter. State of Wyoming boosted its holdings in shares of Zentalis Pharmaceuticals by 30.1% during the 1st quarter. State of Wyoming now owns 45,176 shares of the company’s stock valued at $72,000 after buying an additional 10,460 shares in the last quarter. Finally, AQR Capital Management LLC grew its position in shares of Zentalis Pharmaceuticals by 177.6% in the 1st quarter. AQR Capital Management LLC now owns 619,330 shares of the company’s stock worth $985,000 after buying an additional 396,233 shares during the period.

Zentalis Pharmaceuticals Stock Performance

ZNTL stock opened at $1.37 on Friday. The stock has a market capitalization of $98.98 million, a price-to-earnings ratio of -0.66 and a beta of 1.75. The firm’s 50-day moving average price is $1.39 and its two-hundred day moving average price is $1.46. Zentalis Pharmaceuticals has a 12-month low of $1.01 and a 12-month high of $3.32.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Monday, November 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.12. Equities analysts predict that Zentalis Pharmaceuticals will post -2.42 EPS for the current year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.